$SXTP
60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp

$sxtp Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023070884 Filed on August 25, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q4
Revenue	$51.19K	$59.53K	$511.2K
YoY Change	-90.84%	31.79%
Cost Of Revenue	$71.20K	$184.0K	$432.4K
YoY Change	-76.89%	111.18%
Gross Profit	-$20.01K	-$124.4K	$78.84K
YoY Change	-107.99%	196.67%
Gross Profit Margin	-39.09%	-209.04%	15.42%
Selling, General & Admin	$1.314M	$462.8K	$1.304M
YoY Change	56.54%
% of Gross Profit			1653.63%
Research & Development	$263.7K	$203.9K	$525.6K
YoY Change	-44.73%	-11.89%
% of Gross Profit			666.62%
Depreciation & Amortization	$5.485K	$6.901K	$9.240K
YoY Change	-76.69%	0.0%
% of Gross Profit			11.72%
Operating Expenses	$1.577M	$666.7K	$1.829M
YoY Change	19.83%	4.62%
Operating Profit	-$1.522M	-$788.0K	-$1.750M
YoY Change	42.79%	14.71%
Interest Expense	$40.11K	$1.100M	-$4.504M
YoY Change	-101.27%	21.44%
% of Operating Profit
Other Income/Expense, Net	-$70.49K	-$1.064M	-$43.24K
YoY Change	136.46%
Pretax Income	$4.174M	-$3.344M	-$6.177M
YoY Change	-198.0%	55.53%
Income Tax	$63.00	$63.00	$500.00
% Of Pretax Income	0.0%
Net Earnings	$4.183M	-$3.337M	-$6.182M
YoY Change	-198.24%	55.41%
Net Earnings / Revenue	8172.22%	-5604.64%	-1209.23%
Basic Earnings Per Share	$0.77	-$1.40
Diluted Earnings Per Share	$0.77	-$1.40	-$1.11
COMMON SHARES
Basic Shares Outstanding	5.800M shares	2.378M shares
Diluted Shares Outstanding	5.319M shares	2.378M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.219M	$19.07K	$264.9K
YoY Change	404.91%
Cash & Equivalents	$2.219M	$19.07K	$264.9K
Short-Term Investments
Other Short-Term Assets	$5.940M	$5.065M	$269.6K
YoY Change	3572.06%
Inventory	$598.3K	$465.5K	$518.6K
Prepaid Expenses
Receivables	$138.0K	$125.5K	$45.97K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.895M	$5.675M	$1.099M
YoY Change	484.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.836K	$7.498K	$33.95K
YoY Change	-92.76%
Goodwill
YoY Change
Intangibles	$225.0K	$206.4K	$164.3K
YoY Change
Long-Term Investments
YoY Change
Other Assets		$1.431M
YoY Change
Total Long-Term Assets	$255.4K	$1.684M	$198.2K
YoY Change	52.95%
TOTAL ASSETS
Total Short-Term Assets	$8.895M	$5.675M	$1.099M
Total Long-Term Assets	$255.4K	$1.684M	$198.2K
Total Assets	$9.150M	$7.359M	$1.297M
YoY Change	441.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$271.6K	$1.058M	$758.7K
YoY Change	-40.19%
Accrued Expenses	$26.80K	$39.47K	$13.00K
YoY Change	-20.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$23.54M	$0.00
YoY Change
Long-Term Debt Due	$8.770K	$555.0K	$21.33M
YoY Change		-43.33%
Total Short-Term Liabilities	$2.481M	$28.86M	$23.92M
YoY Change	18.99%
LONG-TERM LIABILITIES
Long-Term Debt		$24.65M	$1.270M
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$255.0K
YoY Change	-100.0%
Total Long-Term Liabilities	$152.6K	$1.373M	$1.525M
YoY Change	-99.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.481M	$28.86M	$23.92M
Total Long-Term Liabilities	$152.6K	$1.373M	$1.525M
Total Liabilities	$2.634M	$30.24M	$24.87M
YoY Change	-88.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$30.57M	-$34.75M	-$28.82M
YoY Change
Common Stock	$580.00	$238.00	$239.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.554M	-$22.30M	-$23.58M
YoY Change
Total Liabilities & Shareholders Equity	$9.150M	$7.359M	$1.297M
YoY Change	441.87%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q4
OPERATING ACTIVITIES
Net Income	$4.183M	-$3.337M	-$6.182M
YoY Change	-198.24%	55.41%
Depreciation, Depletion And Amortization	$5.485K	$6.901K	$9.240K
YoY Change	-76.69%	0.0%
Cash From Operating Activities	-$3.753M	-$313.5K	-$65.98K
YoY Change	297.57%
INVESTING ACTIVITIES
Capital Expenditures	$27.91K	$18.13K	$58.64K
YoY Change	1773.15%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$27.91K	-$18.13K	-$58.64K
YoY Change	1773.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.971M	321.1K	-68.63K
YoY Change	362.75%
NET CHANGE
Cash From Operating Activities	-3.753M	-313.5K	-65.98K
Cash From Investing Activities	-27.91K	-18.13K	-58.64K
Cash From Financing Activities	5.971M	321.1K	-68.63K
Net Change In Cash	2.190M	-10.55K	-193.3K
YoY Change	535.1%
FREE CASH FLOW
Cash From Operating Activities	-$3.753M	-$313.5K	-$65.98K
Capital Expenditures	$27.91K	$18.13K	$58.64K
Free Cash Flow	-$3.781M	-$331.6K	-$124.6K
YoY Change	299.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41719
	dei	Entity Registrant Name EntityRegistrantName	60 DEGREES PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2406880
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1025 Connecticut Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	NW Suite 1000
	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
	dei	Entity Address City Or Town EntityAddressCityOrTown	Washington
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20036
	dei	City Area Code CityAreaCode	(202)
	dei	Local Phone Number LocalPhoneNumber	327-5422
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5799535	shares
CY2023Q2	us-gaap	Cash Cash	19070	usd
CY2022Q4	us-gaap	Cash Cash	264865	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	125470	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45965	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4849473	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	200967	usd
CY2023Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	215173	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	68629	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	465515	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	518578	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	5674701	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1099004	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7498	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21300	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39070	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12647	usd
CY2023Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	1431092	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	206377	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	164255	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	1676539	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	176902	usd
CY2023Q2	us-gaap	Assets Assets	7358738	usd
CY2022Q4	us-gaap	Assets Assets	1297206	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1058321	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	758668	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39470	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13000	usd
CY2023Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	295000	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	325000	usd
CY2023Q2	sxtp	Related Party Notes Netincluding Accrued Interest RelatedPartyNotesNetincludingAccruedInterest	370066	usd
CY2022Q4	sxtp	Related Party Notes Netincluding Accrued Interest RelatedPartyNotesNetincludingAccruedInterest	195097	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	4276609	usd
CY2023Q2	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	8772	usd
CY2022Q4	sxtp	Sbaeid Lincluding Accrued Interest Current SBAEIDLincludingAccruedInterestCurrent	2750	usd
CY2023Q2	us-gaap	Senior Notes Current SeniorNotesCurrent	23539996	usd
CY2023Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1105122	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	16855887	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2084916	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1129840	usd
CY2023Q2	sxtp	Derivative Liabilities Related Parties DerivativeLiabilitiesRelatedParties	361175	usd
CY2022Q4	sxtp	Derivative Liabilities Related Parties DerivativeLiabilitiesRelatedParties	364360	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	28862838	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23921211	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	255000	usd
CY2023Q2	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	152594	usd
CY2022Q4	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	160272	usd
CY2023Q2	us-gaap	Senior Long Term Notes SeniorLongTermNotes	1220155	usd
CY2022Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	1109783	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1372749	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1525055	usd
CY2023Q2	us-gaap	Liabilities Liabilities	30235587	usd
CY2022Q4	us-gaap	Liabilities Liabilities	25446266	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	238	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	239	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12379462	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5164461	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	72044	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	73708	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-34751764	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28815148	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-22300020	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-23576740	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-576829	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-572320	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22876849	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24149060	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7358738	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1297206	usd
CY2023Q2	us-gaap	Revenues Revenues	59532	usd
CY2022Q2	us-gaap	Revenues Revenues	45173	usd
	us-gaap	Revenues Revenues	76704	usd
	us-gaap	Revenues Revenues	92197	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	183977	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	87120	usd
	us-gaap	Cost Of Revenue CostOfRevenue	257097	usd
	us-gaap	Cost Of Revenue CostOfRevenue	177254	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-124445	usd
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-41947	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-180393	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-85057	usd
CY2023Q2	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	3116	usd
CY2022Q2	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	-7740	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	7408	usd
	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	109407	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-121329	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-49687	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-172985	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	24350	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	203872	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	231394	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	327866	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	294451	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	462795	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	405838	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1237809	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	580530	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	666667	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	637232	usd
	us-gaap	Operating Expenses OperatingExpenses	1565675	usd
	us-gaap	Operating Expenses OperatingExpenses	874981	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-787996	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-686919	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1738660	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-850631	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	1099656	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	905519	usd
	us-gaap	Interest Expense InterestExpense	2241085	usd
	us-gaap	Interest Expense InterestExpense	1667736	usd
CY2023Q2	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-399725	usd
CY2022Q2	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-504613	usd
	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-399725	usd
	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-504613	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7968	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1001	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2834	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1001	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-839887	usd
CY2023Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1064849	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-725797	usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	730	usd
CY2022Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-51714	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1321	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-32982	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2555532	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1462847	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4202339	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2206332	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3343528	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2149766	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5940999	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3056963	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	126	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3343591	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2150016	usd
	us-gaap	Profit Loss ProfitLoss	-5941125	usd
	us-gaap	Profit Loss ProfitLoss	-3057463	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7036	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3117	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4509	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1718	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3336555	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2146899	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5936616	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3059181	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3343591	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2150016	usd
	us-gaap	Profit Loss ProfitLoss	-5941125	usd
	us-gaap	Profit Loss ProfitLoss	-3057463	usd
CY2023Q2	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-374	usd
CY2022Q2	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-110989	usd
	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-1664	usd
	us-gaap	Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax	-14433	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3343965	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2261005	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5942789	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3071896	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-7036	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3117	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-4509	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1718	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3336929	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2257888	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5938280	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3073614	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.4
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.54
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2378009	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2349349	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2341274	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2349147	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-18154484	usd
CY2022Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	96556	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-907447	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-18965375	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	185335	usd
CY2022Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-110989	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-2150016	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-21041045	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24149060	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7215000	usd
CY2023Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-1290	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2597534	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-19532884	usd
CY2023Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-374	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3343591	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22876849	usd
	us-gaap	Profit Loss ProfitLoss	-5941125	usd
	us-gaap	Profit Loss ProfitLoss	-3057463	usd
	us-gaap	Depreciation Depreciation	13802	usd
	us-gaap	Depreciation Depreciation	13846	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13192	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1962	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	645336	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	326396	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	24500	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	22135	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	64239	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	12144	usd
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	534408	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	277605	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-839887	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2834	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1001	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	399725	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	504613	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-725797	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	52301	usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	76644	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	79505	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-96030	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	35507	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-116115	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-762	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56986	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	299653	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-25840	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-1426049	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-1198896	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-24453	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22205	usd
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	40000	usd
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	155768	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-726168	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-636944	usd
	us-gaap	Payments For Software PaymentsForSoftware	15419	usd
	us-gaap	Payments For Software PaymentsForSoftware	2907	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21419	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2907	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	146544	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	185335	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	650000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	800000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	305000	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	250000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	250000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	503456	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1290335	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1664	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	14433	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-245795	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	636051	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264865	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115399	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19070	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	751450	usd
	us-gaap	Stock Issued1 StockIssued1	7215000	usd
	sxtp	Additions To Rou Assets For Lease Renewal AdditionsToROUAssetsForLeaseRenewal	50922	usd
	sxtp	Additions To Lease Liabilities For Lease Renewal AdditionsToLeaseLiabilitiesForLeaseRenewal	50570	usd
	sxtp	Conversion Of60 Pllc Member Units To Common Stock ConversionOf60PLLCMemberUnitsToCommonStock	4979365	usd
	sxtp	Debt Discount Recorded In Connection With Derivative Liabilities DebtDiscountRecordedInConnectionWithDerivativeLiabilities	650000	usd
	sxtp	Debt Discount Recorded In Connection With Derivative Liabilities DebtDiscountRecordedInConnectionWithDerivativeLiabilities	1105000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"><b>1.</b></td><td><b>NATURE OF OPERATIONS</b></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, 2022 and merged on the same day with 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September 9, 2010 (“60P LLC”). 60 Degrees Pharmaceuticals, Inc. and its subsidiaries (referred to collectively as the “Company”, “60P”, or “60 Degrees Pharmaceuticals”) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. 60P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. Currently, 60P’s pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir. The Company’s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Initial Public Offering</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 14, 2023, the Company closed its initial public offering consisting of 1,415,095 units at a price of $5.30 per unit for approximately $6,454,300 in net proceeds, after deducting the underwriting discount and commission and other estimated offering expenses payable by the Company. Each unit consisted of one share of common stock of the Company, par value $0.0001 per share, one tradeable warrant to purchase one share of common stock at an exercise price of $6.095 per share, and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise price of $6.36 per share (the “IPO”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The units were offered and sold pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2023 (the “Registration Statement”) and the final prospectus filed with the Commission pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective by the Commission on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the completion of the IPO, among other things, certain of the Company’s then-outstanding convertible debt were converted into shares of common stock. See Notes 9 and 12 for more information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern for one year from the date these financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In view of these matters, continuation as a going concern is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financial requirements, raise additional capital, and the success of its future operations. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a public offering until such a time as a business combination or other profitable investment may be achieved.</p>
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2023Q2	us-gaap	Investment Owned Percent Of Net Assets InvestmentOwnedPercentOfNetAssets	0.8753	pure
CY2023Q2	us-gaap	Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee	1	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Use of Estimates</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, deferred compensation, derivative liabilities, certain promissory notes carried at fair value, and valuation allowance for the deferred tax asset.</p>
	us-gaap	Financing Receivable Modification To Total Financing Receivables Percent FinancingReceivableModificationToTotalFinancingReceivablesPercent	0.24	pure
	us-gaap	Financing Receivable Modification To Total Financing Receivables Percent FinancingReceivableModificationToTotalFinancingReceivablesPercent	0.76	pure
CY2022	us-gaap	Financing Receivable Modification To Total Financing Receivables Percent FinancingReceivableModificationToTotalFinancingReceivablesPercent	0.30	pure
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Reclassifications</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated results of operations and comprehensive loss, shareholders’ and members’ deficit, or cash flows.</p>
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	279061	usd
CY2023Q2	sxtp	Fair Value Commitment Date FairValueCommitmentDate	954725	usd
CY2023Q2	us-gaap	Costs Incurred Development Costs CostsIncurredDevelopmentCosts	6000	usd
	us-gaap	Costs Incurred Development Costs CostsIncurredDevelopmentCosts	39895	usd
CY2023Q2	us-gaap	Development Costs DevelopmentCosts	0	usd
	us-gaap	Development Costs DevelopmentCosts	0	usd
CY2022Q4	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue	1494200	usd
CY2023Q1	sxtp	Fair Value Mark To Market Adjustment FairValueMarkToMarketAdjustment	5134	usd
	us-gaap	Franchisor Costs FranchisorCosts	250	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1000000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1000	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	30000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	30000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Concentrations</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and lending.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant customers represent any customer whose business makes up 10% of our receivables or revenues. 100% of receivables as of June 30, 2023 (consisting of two significant customers at 76% and 24%) and 100% of total net revenues for the three months ended June 30, 2023 were generated by one significant customer (100% for the three months ended June 30, 2022 consisting of one significant customer). At December 31, 2022, 98% of the Company’s receivables, consisting of three customers and two significant at 59% and 39%, were generated from significant customers. 100% of the revenues were generated by the Company from one significant customer during the six months ended June 30, 2023 (100% for the six months ended June 30, 2022 consisting of one significant customer). Currently, the Company has exclusive relationships with distributors in Australia and Europe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A failure to perform by any of our current distributors would create disruption for patients in those markets. The US government has historically been the Company’s largest customer through a purchase support contract and a clinical study. Both of those activities ended during 2022 and near-term receivables and revenues from the government are not anticipated to be significant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company first started working on tafenoquine all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (“API”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2023, 84% (85% at December 31, 2022) of the Company’s non-related party debt is held by Knight Therapeutics, the senior secured lender and also a publicly traded Canadian company. The amount of senior secured debt with Knight Therapeutics currently limits the Company’s ability to access additional credit and management has been informed that additional lending with Knight Therapeutics is not currently possible.</p>
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.84	pure
CY2022	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.85	pure
CY2023Q1	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue	1499334	usd
CY2023Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	203872	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	327866	usd
CY2022Q2	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	231394	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	294451	usd
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	525000	shares
CY2023Q2	us-gaap	Common Stock Shares Held In Employee Trust Shares CommonStockSharesHeldInEmployeeTrustShares	405000	shares
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	1431092	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	0	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	25986087	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	1494200	usd
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5
CY2022Q4	sxtp	Percentage Of Cancelled Shares Issued PercentageOfCancelledSharesIssued	0.61	pure
CY2022Q4	sxtp	Percentage Of Cancelled Shares Outstanding PercentageOfCancelledSharesOutstanding	0.61	pure
	us-gaap	Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares	238601	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	513000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	0	shares
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1100000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	0	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2378009	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2378009	shares
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	397487	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	397487	usd
CY2022Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	97486	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	301112	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	183943	usd
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	42617	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	63062	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	741216	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	741978	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	275701	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	223400	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	465515	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	518578	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	148202	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	148202	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	140704	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	126902	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7498	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21300	usd
	us-gaap	Depreciation Depreciation	13802	usd
	us-gaap	Depreciation Depreciation	13846	usd
CY2023Q2	us-gaap	Depreciation Depreciation	6901	usd
CY2022Q2	us-gaap	Depreciation Depreciation	6901	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21815841	usd
CY2023Q2	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	1064849	usd
CY2023Q2	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	659306	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	23539996	usd
	us-gaap	Line Of Credit Facility Increase Decrease Other Net LineOfCreditFacilityIncreaseDecreaseOtherNet	725797	usd
CY2023Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	161032	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	145613	usd
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	66965	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	27070	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	227997	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	172683	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-21620	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-8428	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	206377	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	164255	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13192	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1962	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6017	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	952	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts	109241	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	100000	usd
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	60000	usd
CY2022Q2	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	400000	usd
CY2022Q2	us-gaap	Deferred Compensation Cash Based Arrangements Liability Current DeferredCompensationCashBasedArrangementsLiabilityCurrent	100000	usd
CY2022Q2	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	245000	usd
CY2022Q2	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	155000	usd
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	57198	usd
CY2022Q2	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	12500	usd
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	1	pure
CY2022Q2	us-gaap	Deferred Compensation Cash Based Arrangements Liability Current DeferredCompensationCashBasedArrangementsLiabilityCurrent	38900	usd
CY2022Q2	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	60000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	65000	shares
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Exercise Price DeferredCompensationArrangementWithIndividualExercisePrice	5
CY2022Q4	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	325000	usd
CY2023Q1	us-gaap	Deferred Compensation Arrangement With Individual Shares Issued DeferredCompensationArrangementWithIndividualSharesIssued	65000	shares
CY2023Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.09	pure
CY2022Q4	us-gaap	Loans Payable LoansPayable	20596595	usd
CY2017Q4	sxtp	Promissory Note Amount PromissoryNoteAmount	750000	usd
CY2017Q4	us-gaap	Long Term Debt Maturities Repayment Terms LongTermDebtMaturitiesRepaymentTerms	60 days
CY2017Q4	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.05	pure
CY2017Q4	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.10	pure
CY2022Q1	us-gaap	Long Term Debt Maturities Repayment Terms LongTermDebtMaturitiesRepaymentTerms	30 days
CY2017Q4	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	120683	usd
CY2017Q4	us-gaap	Interest Costs Incurred InterestCostsIncurred	1767	usd
CY2023Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	24613	usd
CY2022Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	48759	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	31352	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	28401	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	61614	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	55813	usd
	us-gaap	Interest Expense Other InterestExpenseOther	1293549	usd
CY2019Q2	us-gaap	Debt Current DebtCurrent	3000000	usd
CY2019Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2100000	usd
CY2023Q2	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	23539996	usd
CY2023Q2	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure	2325277	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	24645118	usd
CY2023Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	1220155	usd
CY2022Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	17965670	usd
CY2022Q4	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure	16855887	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1109783	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	17965670	usd
CY2022Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10770037	usd
CY2023Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	7000000	usd
	sxtp	Initial Public Offering Discount Percentages InitialPublicOfferingDiscountPercentages	0.15	pure
	sxtp	Common Stock Outstanding Percentages CommonStockOutstandingPercentages	0.199	pure
	sxtp	Payment Of Milestones PaymentOfMilestones	10000000	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	30000	usd
CY2023Q1	sxtp	Cumulative Dividend Percentage CumulativeDividendPercentage	0.06	pure
CY2023Q2	sxtp	Common Stock Ownership Percentage CommonStockOwnershipPercentage	0.199	pure
CY2022Q1	sxtp	Equal Royalty Pay To Lender Percentage EqualRoyaltyPayToLenderPercentage	3.5	usd
CY2023Q1	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	839887	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	21520650	usd
CY2023Q1	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	-339052	usd
CY2023Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	634243	usd
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	3000000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	279061	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	2720939	usd
CY2022Q4	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	1555670	usd
CY2022Q4	sxtp	Debenture Debenture	4276609	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000	usd
CY2020Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0375	pure
CY2020Q2	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	731	usd
CY2022Q4	us-gaap	Interest Paid Net InterestPaidNet	731	usd
CY2023Q2	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	161366	usd
CY2022Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	163022	usd
	sxtp	Long Term Debt Current Maturitie LongTermDebtCurrentMaturitie	8772	usd
CY2023Q2	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	152594	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	2750	usd
CY2022Q4	sxtp	Sbaeid Lincluding Accrued Interest Non Current SBAEIDLincludingAccruedInterestNonCurrent	160272	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2804	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	147196	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	150000	usd
	sxtp	Payment Terms Balloon Payment To Be Paid PaymentTermsBalloonPaymentToBePaid	32383	usd
CY2023Q2	sxtp	Short Term Advance Received ShortTermAdvanceReceived	50000	usd
CY2023Q2	sxtp	Short Term Advance Received ShortTermAdvanceReceived	250000	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	1483888	usd
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	979275	usd
CY2022Q2	us-gaap	Derivative Cost Of Hedge DerivativeCostOfHedge	504613	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	954725	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	555000	usd
CY2023Q2	us-gaap	Derivative Cost Of Hedge DerivativeCostOfHedge	399725	usd
CY2023Q2	sxtp	Fair Value Mark To Market Adjustment FairValueMarkToMarketAdjustment	-7968	usd
CY2023Q2	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue	2446091	usd
	sxtp	Fair Value Commitment Date FairValueCommitmentDate	1483888	usd
	sxtp	Fair Value Mark To Market Adjustment FairValueMarkToMarketAdjustment	1001	usd
CY2022Q2	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue	1484889	usd
CY2023Q2	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	7968	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	2834	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1001
CY2023Q2	us-gaap	Share Price SharePrice	5.3
CY2022Q2	us-gaap	Share Price SharePrice	5
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.151	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.997	pure
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y11M26D
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y11M26D
CY2022Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.048	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	sxtp	Ipo Probabilityprior To Note Maturity Datein Dollars IPOProbabilitypriorToNoteMaturityDateinDollars	0.95	pure
CY2022Q2	sxtp	Ipo Probabilityprior To Note Maturity Datein Dollars IPOProbabilitypriorToNoteMaturityDateinDollars	0.95	pure
CY2023Q2	us-gaap	Share Price SharePrice	5.3
CY2022Q4	us-gaap	Share Price SharePrice	5
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.019	pure
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y4M20D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0406	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	sxtp	Ipo Probabilityprior To Note Maturity Datein Dollars IPOProbabilitypriorToNoteMaturityDateinDollars	0.95	pure
CY2022	sxtp	Ipo Probabilityprior To Note Maturity Datein Dollars IPOProbabilitypriorToNoteMaturityDateinDollars	0.95	pure
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	126	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	250	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500	usd
CY2023Q2	us-gaap	Product Liability Contingency Accrual Discount Rate ProductLiabilityContingencyAccrualDiscountRate	0.15	pure
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	27985	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	13992	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	41977	usd
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	2507	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	39470	usd
CY2023Q2	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	39470	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.15	pure
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	13859	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	12974	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	27366	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	25947	usd
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	43581	usd
CY2023Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	1108337	shares
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	9.6	usd
CY2023Q3	us-gaap	Common Unit Outstanding CommonUnitOutstanding	5799535	shares
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2023Q2	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2349147	shares
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	sxtp	Additions To Rou Assets For Lease Renewal AdditionsToROUAssetsForLeaseRenewal		usd
	sxtp	Additions To Lease Liabilities For Lease Renewal AdditionsToLeaseLiabilitiesForLeaseRenewal		usd
	sxtp	Conversion Of60 Pllc Member Units To Common Stock ConversionOf60PLLCMemberUnitsToCommonStock		usd
CY2023Q2	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies		usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent		usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet		usd
CY2023Q2	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts		usd
CY2023Q2	sxtp	Debenture Debenture		usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths		usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo		usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree		usd
CY2023Q2	us-gaap	Long Term Debt Maturing In Years Two And Three LongTermDebtMaturingInYearsTwoAndThree		usd
CY2021Q4	us-gaap	Derivative Instruments In Hedges Liabilities At Fair Value DerivativeInstrumentsInHedgesLiabilitiesAtFairValue		usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001946563

Files In Submission

Name	View Source	Status
0001213900-23-070884-index-headers.html	Edgar Link	pending
0001213900-23-070884-index.html	Edgar Link	pending
0001213900-23-070884.txt	Edgar Link	pending
0001213900-23-070884-xbrl.zip	Edgar Link	pending
f10q0623ex31-1_60degrees.htm	Edgar Link	pending
f10q0623ex31-2_60degrees.htm	Edgar Link	pending
f10q0623ex32-1_60degrees.htm	Edgar Link	pending
f10q0623ex32-2_60degrees.htm	Edgar Link	pending
f10q0623_60degrees.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0623_60degrees_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sxtp-20230630.xsd	Edgar Link	pending
sxtp-20230630_cal.xml	Edgar Link	unprocessable
sxtp-20230630_lab.xml	Edgar Link	unprocessable
sxtp-20230630_def.xml	Edgar Link	unprocessable
sxtp-20230630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SXTP
60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp

2023 Q3 Form 10-Q Financial Statement

#000121390023070884 Filed on August 25, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SXTP 60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp

2023 Q3 Form 10-Q Financial Statement

#000121390023070884 Filed on August 25, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SXTP
60 DEGREES PHARMACEUTICALS, INC. Stock $sxtp